Palumbo Wealth Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$326K Hold
4,000
0.08% 162
2025
Q4
$319K Sell
4,000
-8,851
-69% -$655K 0.08% 164
2025
Q3
$238K Buy
+12,851
New +$692K 0.08% 161
2025
Q1
Sell
-4,000
Closed -$203K 188
2024
Q4
$203K Hold
4,000
0.08% 152
2024
Q3
$255K Hold
4,000
0.1% 122
2024
Q2
$237K Hold
4,000
0.1% 118
2024
Q1
$230K Hold
4,000
0.1% 115
2023
Q4
$228K Buy
+4,000
New +$188K 0.12% 111
2023
Q3
Sell
-4,000
Closed -$208K 117
2023
Q2
$208K Hold
4,000
0.13% 102
2023
Q1
$217K Buy
+4,000
New +$226K 0.14% 88

Other funds holding BIB

Palumbo Wealth Management's BIB Position: Q1 2026 in Review

Palumbo Wealth Management held its ProShares Ultra NASDAQ Biotechnology (BIB) position steady in Q1 2026 at 4,000 shares worth $326K. The position accounts for 0.08% of the portfolio, ranked #162.

Palumbo Wealth Management first reported a position in BIB in Q1 2023 and has held it in 10 quarters since. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

  • Palumbo Wealth Management held 4,000 shares of ProShares Ultra NASDAQ Biotechnology worth $326K as of Q1 2026.
  • Palumbo Wealth Management left its ProShares Ultra NASDAQ Biotechnology share count unchanged in Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology made up 0.08% of Palumbo Wealth Management's portfolio in Q1 2026, its #162 holding.
  • Palumbo Wealth Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2023 and has held it in 10 quarters since.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Palumbo Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.